The Dutch-Danish Health Alliance

What is the Alliance?

Members of the Alliance all share an interest in the long-term sustainability of the innovative life science industry in the Netherlands. The strategic focus of the Alliance lies on three pillars:

1. Chronic Disease Management Policy
2. Innovation
3. Life Science Strategy

This initiative represents a commitment to work collaboratively with both the public and private sectors to ensure that the Life Sciences industry remains a driver of employment, economic resilience, and better health outcomes.

It aims to function not only as a sparring partner for stakeholders but also as an emerging think tank that fosters dialogue, knowledge-sharing, and joint action. By exchanging data, insights, and best practices from both healthcare systems, the alliance aspires to contribute constructively to public discourse and inspire sustainable policy development.

Read more about the Alliance in our Inspiration Paper.

The Need for the Alliance

Healthcare challenges today are complex and interconnected. Across Europe, health systems face increasing pressures: from the rising prevalence of chronic diseases and aging population to workforce shortages and the need for sustainable innovation. These issues affect not only individual patients but also broader societal and economic systems.
As life expectancy increases and retirement is delayed, ensuring that people remain healthy and active in the workforce has become a central concern in shaping future healthcare strategies.

Members of the Alliance

The founding members of the Alliance consist of three leading Danish Life Science companies, each bringing specialized expertise and a long-standing commitment to improving patient outcomes: ALK Albelló, Coloplast, and Novo Nordisk.

All three companies established a local entity in the Netherlands in the 1980s, meaning nearly 50 years of presence and commitment to Dutch patients. All members are foundation-based companies. The foundations thus have mandate to develop social and economic benefits to all; not just the shareholders. A significant amount of their revenue is redirected to support research and education as well as contribute to civil society, culture, and the economy.